Drug intelligence / Profile preview

VB.7

Development stage: Unknown
Lead developer: Adjuvax
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

**VB.7** is an Adjuvax formulated saponin-combination vaccine adjuvant. It is listed by Adjuvax as commercially available for purchase and also as a preclinical saponin-adjuvant program. Its intended role is to enhance immune responses to co-administered vaccine antigens; no specific molecular target, vaccine antigen, indication, route of administration, or regulatory approval for a defined human or veterinary vaccine is disclosed in the available public product listing. ([adjuvax.net](https://adjuvax.net/products/))

Beyond the preview

Go deeper on VB.7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB.7.

Explore the full profile